The Cardiovascular Safety of Diabetes Drugs — Insights from the Rosiglitazone Experience — NEJM

Retweeted NEJM (@NEJM): Perspective: as signal of CV harm w/ rosiglitazone has faded, should FDA policy on #diabetes drugs change? http://t.co/aAneBgbjoY #ESC2013

via VAT ENGPlus Combo | VATPlus | MotionTrak http://t.co/aAneBgbjoY